Opexa Therapeutics (Nasdaq: OPXA) is a biotechnology company dedicated to the development of patient-specific cellular therapies for the treatment of autoimmune diseases such as multiple sclerosis (MS) and diabetes. The company’s product candidates have the potential to offer enhanced efficacy, safety and tolerability to address the significant unmet medical needs in several large patient populations.

Opexa’s lead product candidate is Tovaxin®, a novel T-cell vaccine for the treatment of MS that is specifically tailored to each patient’s disease profile. Top-line results from the Phase IIb Tovaxin for Early Relapsing Multiple Sclerosis (TERMS) study demonstrated a positive trend in reduction in annualized relapse rate for Tovaxin-treated patients as compared to placebo, as well as an excellent safety profile with no serious adverse events related to Tovaxin treatment.

Upcoming Webcasts

November 11, 2008, 5:45 p.m.

Rodman & Renshaw in New York Annual Global Investment Conference